Current treatments for lung cancer employ ... In a preclinical study (“Overcoming microenvironmental resistance to PD-1 blockade in genetically engineered lung cancer models“), published ...

Despite compelling antitumour activity of antibodies targeting the programmed death 1 (PD-1): programmed death ligand 1 (PD-L1) immune checkpoint in lung cancer, resistance to these therapies has ...

This triple combination therapy, targeting CDK4/6, MEK, and PD-L1, resulted in prolonged MPNST regression and improved survival, although most tumors eventually developed drug resistance.

This case report describes a durable response (by RECIST 1.1 criteria) in a patient with a challenging clinical profile—a PD-L1 positive ... Mimura K. Current status of immune checkpoint ...

Patient getting vaccinated New research suggests that mRNA COVID-19 vaccines can elevate PD-L1 expression levels in patients with advanced non-small cell lung cancer. New research suggests that ...

“Gastric cancer remains an area of high unmet need, where the majority of patients develop disease progression related to tumor resistance ... clinical profile—a PD-L1 positive, HER ...